A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients With Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; IO-202 (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia
- Focus Adverse reactions; First in man
- Sponsors Immune-Onc Therapeutics
- 14 Feb 2025 Status changed from active, no longer recruiting to completed.
- 10 Dec 2024 Updated results from phase 1b study were presented in an Immune-Onc Therapeutics media release.
- 10 Dec 2024 According to an Immune-Onc Therapeutics media release, new finding from this study were highlighted in an oral presentation at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, California.